Antibody Drug Conjugates
In the ever-evolving field of cancer research, few innovations have generated as much optimism as antibody-drug conjugates (ADCs). Therefore, they are often called “smart bombs” or “guided missiles.” They combine the specificity of immunotherapy with the potency of chemotherapy. Essentially, as a new class of therapeutics, ADCs deliver targeted drugs that kill cancer cells with minimal toxicity to healthy tissues.
Consequently, as cancer treatments advance, ADCs are emerging as a breakthrough in precision oncology.
What Are Antibody-Drug Conjugates?
ADCs are composed of three components of interest:
- Monoclonal Antibody: A manufacturer-produced antibody that recognizes and binds to an antigen present on the cancer cell with specificity.
- Cytotoxic Drug: A chemotherapy drug that is so therapeutically potent that one could not deliver it generally without causing severe harm.
- Linker: A molecular connector between the antibody and the payload that releases the payload once within the targeted cancer cell.
ADCs deliver the payload directly to the cancer cells, minimizing the possibility of providing detoxifying effects to healthy tissues. To add to their uniqueness, antibody-drug conjugates not only show elevated efficacy. It also correlated with decreases in side effects when compared to traditional chemotherapy.
Why are ADCs important in treating cancer?
Traditional chemotherapy targets rapidly-dividing cells beyond cancer cells, as well as normal healthy cells. ADCs are a more selective therapy because they work directly on the cancer cell and spare healthy tissue.
Current Innovation and Challenges with ADCs
ADCs have challenges, even though they are very promising. For example, many patients develop resistance to ADCs over time, and some experience unique toxicities that we did not see with traditional chemotherapy.
To overcome some of these challenges, scientists are optimizing each part of the ADC:
- They design antibodies that have greater specificity.
- They optimize linkers for better stability in circulation and better release in the tumor.
- Finally, payloads are becoming more potent and selective.
In addition, scientists are developing new formats, including:
- Bispecific ADCs, which target two antigens at once, thereby increasing precision and possibly bypassing resistance.
- Probody-drug conjugates (PDCs), which remain inactive until they penetrate the tumor microenvironment, consequently reducing off-target effects.
- Dual-drug ADCs, which carry two different cytotoxic therapeutics to avoid chemotherapy resistance from tumor heterogeneity.
- Immune-stimulating ADCs and protein-degrader ADCs, which attack a tumor via multiple modes to enhance the immune response or target proteins that support the cancer.
These innovations hope to expand the therapeutic window of ADCs, making them safer and more effective.
Practical Applications and Clinical Impact
ADCs are already proving effective against various tumors, particularly breast cancer, where doctors use them to optimize patient survival rates. The application of ADCs across tumors with heterogeneous antigen expression (where some tumor cells lack a surface marker) offers opportunities for improved patient outcomes.
Moreover, clinical data also suggest that some newer ADCs can work even when tumor cells express low or variable levels of antigens. Therefore, this provides new opportunities for treating tumors with resistance or those that are difficult to target.
ADCs do have distinct adverse effects. For instance, some patients experience toxicity to the lungs (pneumonitis), eye issues, or skin reactions. Therefore, healthcare providers must monitor and manage these adverse effects carefully. To that end, providers are now implementing different mitigation or monitoring strategies, which include assessments before, during, and after therapy.
In addition, the next generation of therapies—such as immune-stimulating antibody conjugates, engineered toxin bodies, and radioligand conjugates—will build on the success of ADCs and improve the therapeutic index. Ultimately, the goal is to maximize anti-cancer activity while limiting systemic toxicity.
ADCs in the Pipeline: An Industry Perspective
Biopharmaceutical companies like Bristol Myers Squibb are dedicating significant resources to developing ADCs in clinical trials. The company sees ADCs as central to its precision medicine platform, which focuses on matching the right drug to the right patient.
Recent Milestones in ADC Development
The year 2025 marked many significant breakthroughs that show the evolving momentum of ADCs:
- ADC Therapeutics was awarded $100 million in funding and extended its operational runway to 2028.
- Trodelvy plus Keytruda showed superiority over the standard of care in a pivotal Phase 3 study in metastatic triple-negative breast cancer.
- The FDA approved DATROWAY (datopotamab deruxtecan-dlnk) for HR-positive, HER2-negative breast cancer, based on positive Phase 3 data showing a 37% reduction in disease progression.
Consequently, these successes highlight how quickly ADCs are changing oncology clinics.
Conclusion: An Optimistic Perspective
Antibody-drug conjugates are an innovative development in cancer therapy. They combine immunotherapy and chemotherapy into one targeted treatment. With new technologies and various formats, ADCs are expected to become a major synergistic component of cancer therapy for many tumor types.
With ongoing research, better design, and expanded application, ADCs should not only extend the lives of cancer patients but also improve their quality of life. In time, targeted therapies may transform cancer from a life-threatening disease into a manageable or curable condition.
About the Author
